Despite a Q1 beat, Illumina has seen its share price decline over the last week (five trading sessions). The only negative from the earnings announcement was the margin contraction. Illumina has been investing more into R&D and its SG&A expenses also rose in Q1, pushing the overall operating costs..
Despite a Q1 beat, Illumina has seen its share price decline over the last week (five trading sessions). The only negative from the earnings announcement was the margin contraction. Illumina has been investing more into R&D and its SG&A expenses also rose in Q1, pushing the overall operating costs..
Share this Article
Recommended